ATE319089T1 - Behandlung und diagnose von krebs - Google Patents
Behandlung und diagnose von krebsInfo
- Publication number
- ATE319089T1 ATE319089T1 AT97934922T AT97934922T ATE319089T1 AT E319089 T1 ATE319089 T1 AT E319089T1 AT 97934922 T AT97934922 T AT 97934922T AT 97934922 T AT97934922 T AT 97934922T AT E319089 T1 ATE319089 T1 AT E319089T1
- Authority
- AT
- Austria
- Prior art keywords
- prostate
- specific membrane
- prostate specific
- cancerous
- biological agents
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2212596P | 1996-07-18 | 1996-07-18 | |
US08/838,682 US6107090A (en) | 1996-05-06 | 1997-04-09 | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE319089T1 true ATE319089T1 (de) | 2006-03-15 |
Family
ID=26695548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97934922T ATE319089T1 (de) | 1996-07-18 | 1997-07-17 | Behandlung und diagnose von krebs |
Country Status (16)
Country | Link |
---|---|
US (4) | US6107090A (de) |
EP (2) | EP0956506B1 (de) |
JP (2) | JP4503102B2 (de) |
CN (2) | CN100344970C (de) |
AT (1) | ATE319089T1 (de) |
AU (1) | AU733544C (de) |
BR (1) | BR9710487A (de) |
CA (1) | CA2261018C (de) |
DE (1) | DE69735368T2 (de) |
EA (2) | EA200400179A1 (de) |
ES (1) | ES2255723T3 (de) |
HK (1) | HK1025631A1 (de) |
IL (2) | IL127979A0 (de) |
NZ (2) | NZ524036A (de) |
PT (1) | PT956506E (de) |
WO (1) | WO1998003873A1 (de) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7105159B1 (en) * | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6569432B1 (en) * | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6962981B1 (en) * | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6136311A (en) * | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US20060269532A1 (en) * | 1997-02-25 | 2006-11-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6759515B1 (en) * | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20060024301A1 (en) * | 1997-02-25 | 2006-02-02 | Corixa Corporation | Prostate-specific polypeptides and fusion polypeptides thereof |
US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
US6232287B1 (en) * | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
US6200765B1 (en) | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
FR2791573B1 (fr) * | 1999-03-30 | 2003-04-11 | Pf Medicament | Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate |
EP1710256A1 (de) * | 1999-07-29 | 2006-10-11 | Medarex, Inc. | Humane monoklonale Antikörper gegen Prostata spezifisches Membranantigen |
AU783356B2 (en) * | 1999-07-29 | 2005-10-20 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen |
EP1221053A4 (de) * | 1999-09-13 | 2004-12-22 | Neil H Bander | Verfahren zur isolierung von prostatischen epithelzellen aus sperma |
US20080153119A1 (en) * | 1999-09-24 | 2008-06-26 | Schebo Biotech Ag | Detecting the presence of pyruvate kinase isoenzyme in feces |
WO2001058458A1 (en) | 2000-02-08 | 2001-08-16 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6379550B1 (en) * | 2000-07-24 | 2002-04-30 | Health Research, Inc. | Method for detecting PSA and its molecular forms using thiophilic gel |
US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
AU2002239403A1 (en) * | 2000-12-01 | 2002-06-11 | The Johns Hopkins University | Tissue specific prodrugs |
WO2002096460A1 (en) * | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
US7045605B2 (en) * | 2001-06-01 | 2006-05-16 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
AU2002359244A1 (en) * | 2001-09-05 | 2003-04-28 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases |
WO2003024388A2 (en) | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
US20030124132A1 (en) * | 2001-09-27 | 2003-07-03 | Board Of Regents, The University Of Texas System | Combined compositions for tumor vasculature coaguligand treatment |
US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
US20040161776A1 (en) * | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
EP3184539A3 (de) * | 2001-10-23 | 2017-09-13 | PSMA Development Company L.L.C. | Psma antikörper |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7767803B2 (en) * | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
DK2269656T3 (da) | 2002-07-15 | 2014-11-03 | Univ Texas | Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
EP1581794B1 (de) * | 2003-01-10 | 2008-09-17 | Millennium Pharmaceuticals, Inc. | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
DK1587837T3 (da) | 2003-01-28 | 2012-09-24 | Proscan Rx Pharma Inc | Epitopsekvenser til diagnose og behandling af prostatacancer |
WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
WO2005092286A2 (en) * | 2004-03-29 | 2005-10-06 | The University Of Houston System | Metallic nano-particles and discrete polymer-coated nano-particles |
EP1756166A4 (de) * | 2004-04-19 | 2008-08-27 | Proscan Rx Pharma | Diagnose und behandlung von prostatakrebs |
EP1819277A4 (de) * | 2004-11-12 | 2010-05-05 | Ltd Kpe | Nanoteilchen-vermittelte ultraschalltherapie und diagnostische bilddarstellung |
WO2006086345A2 (en) * | 2005-02-07 | 2006-08-17 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
EP1851251A2 (de) * | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoklonale antikörper gegen ein prostataspezifisches membranantigen, das in fucosyl-resten fehlt |
NZ556661A (en) * | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
WO2006096754A2 (en) * | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
EP1726650A1 (de) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoklonale Antikörper und Einzelkettenantikörper Fragments gegen das zelloberflächen Prostataspezifische Membranantigen |
US7736647B2 (en) * | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
PL1912677T3 (pl) * | 2005-06-20 | 2014-03-31 | Psma Dev Company L L C | Koniugaty przeciwciało PSMA-lek |
CA2623236A1 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
NZ599683A (en) * | 2005-12-20 | 2013-11-29 | Sbi Biotech Co Ltd | Anti-ilt7 antibody |
CA2658276A1 (en) * | 2006-07-18 | 2008-01-24 | Sanofi-Aventis | Antagonist antibody for the treatment of cancer |
WO2008074004A2 (en) * | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
WO2009015263A2 (en) * | 2007-07-25 | 2009-01-29 | Wyeth | Methods for characterizing cell proximity |
WO2009046294A2 (en) | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
KR101573552B1 (ko) | 2007-11-14 | 2015-12-11 | 인벤티오 아게 | 승강실을 구동 및 지탱시키기 위한 승강기 구동장치 및 방법, 대응하는 방법 및 승강실을 감속 및 지탱시키기 위한 제동 장치 및 방법, 및 관련된 방법 |
WO2009127046A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
DK2326350T3 (da) | 2008-09-08 | 2013-12-16 | Psma Dev Company L L C | Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller |
US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
MD36Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare |
MD24Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare |
MD23Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare |
MD35Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
EP2433322A4 (de) | 2009-05-19 | 2015-11-04 | East Penn Mfg Co | Verbundstromabnehmer und verfahren dafür |
US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
EP3511023A1 (de) | 2009-12-02 | 2019-07-17 | Imaginab, Inc. | J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung |
CA3188287A1 (en) | 2010-03-26 | 2011-09-29 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
JP5702944B2 (ja) * | 2010-03-31 | 2015-04-15 | 独立行政法人国立がん研究センター | バイオマーカー |
WO2011133555A2 (en) | 2010-04-20 | 2011-10-27 | The Research Foundation Of State University Of New York | Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration |
CN102939538A (zh) * | 2010-05-07 | 2013-02-20 | 霍夫曼-拉罗奇有限公司 | 用于离体检测细胞的诊断方法 |
WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
WO2012106368A2 (en) | 2011-01-31 | 2012-08-09 | The Regents Of The University Of California | Methods for inhibiting prostate cancer |
US8314566B2 (en) * | 2011-02-22 | 2012-11-20 | Quarkstar Llc | Solid state lamp using light emitting strips |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
CA2874854C (en) | 2012-06-07 | 2023-03-14 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
US20150152187A1 (en) | 2012-06-14 | 2015-06-04 | Ambrx, Inc. | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides |
EP2885002A4 (de) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
LT2900277T (lt) | 2012-12-13 | 2022-04-11 | Immunomedics, Inc. | Antikūnų ir sn-38 imunokonjugatų dozės, skirtos pagerintam veiksmingumui ir sumažintam toksiškumui |
US11242399B2 (en) | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
KR102066319B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
JP6463331B2 (ja) | 2013-03-15 | 2019-01-30 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | 抗ヘプシジン抗体およびその使用 |
JP6908964B2 (ja) | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー,エルエルシー | Psmaリガンドコンジュゲートによる併用療法 |
WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
EP3107577B1 (de) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
PL3151865T3 (pl) | 2014-05-22 | 2022-01-03 | Byondis B.V. | Koniugacja w określonym miejscu leków-łączników z przeciwciałami oraz powstałe w jej wyniku koniugaty przeciwciało-lek (ADCs) |
WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
CA2961774C (en) | 2014-10-07 | 2023-05-23 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
CN104447955B (zh) * | 2014-11-23 | 2018-04-20 | 南京市第一医院 | 一种与psma膜外区靶向性结合的多肽及其应用 |
EP3064507A1 (de) | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon |
WO2016149485A1 (en) | 2015-03-17 | 2016-09-22 | The Regents Of The University Of California | Novel chemoimmunotherapy for epithelial cancer |
ES2929614T3 (es) | 2015-03-17 | 2022-11-30 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-MUC16 y usos de los mismos |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
MX2017014908A (es) | 2015-05-21 | 2018-08-15 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
CA2983597A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3316885B1 (de) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antikörper-sn-38-immunkonjugate mit einem cl2a-linker |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
EP3331564A4 (de) | 2015-08-07 | 2019-05-22 | Imaginab, Inc. | Gegen moleküle gerichtete antigenbindende konstrukte |
EP3192810A1 (de) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma-bindender antikörper und verwendungen davon |
JP7042467B2 (ja) | 2016-05-20 | 2022-03-28 | ハープーン セラピューティクス,インク. | 単鎖可変フラグメントcd3結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
ES2965349T3 (es) | 2016-06-06 | 2024-04-12 | Abzena Uk Ltd | Anticuerpos, usos de los mismos y conjugados de los mismos |
GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス,インク. | 三重特異性タンパク質と使用方法 |
EP3703886A4 (de) | 2017-11-04 | 2021-05-05 | Sona Nanotech | Metallnanopartikel und verfahren zur herstellung davon |
CA3093078A1 (en) | 2018-03-06 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
US12059473B2 (en) | 2018-03-29 | 2024-08-13 | Ambrx, Inc. | Humanized anti-prostate -specific membrane antigen (PSMA) antibody drug conjugates |
CN113286616A (zh) | 2018-05-23 | 2021-08-20 | Adc治疗有限公司 | 分子佐剂 |
EP3587454A1 (de) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimäre antigenrezeptoren, die an prostataspezifisches membranantigen binden |
RS63943B1 (sr) | 2018-07-31 | 2023-02-28 | Heidelberg Pharma Res Gmbh | Humanizovana antitela protiv psma |
WO2020069028A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
USD925928S1 (en) | 2019-03-01 | 2021-07-27 | Simplehuman, Llc | Vanity mirror |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
CN112285082A (zh) * | 2020-10-28 | 2021-01-29 | 上海睿钰生物科技有限公司 | 一种基于细胞直径评价细胞杀伤效力的方法及其应用 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
JPWO2022239720A1 (de) | 2021-05-10 | 2022-11-17 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4824986A (en) | 1985-04-26 | 1989-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Metal chelate protein conjugate |
US4814275A (en) * | 1985-05-13 | 1989-03-21 | E.I. Dupont De Nemours And Company | Monoclonal hybridoma antibody specific for a human epithelial antigen |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US4863854A (en) * | 1985-08-12 | 1989-09-05 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to mucin-like human differentiation antigens |
DE3684578D1 (de) * | 1985-12-17 | 1992-04-30 | Eastern Virginia Medical Autho | Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung. |
US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
EP0232751B1 (de) | 1986-01-23 | 1991-09-11 | E.R. Squibb & Sons, Inc. | 1-Substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und Analoga |
MX174467B (es) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos |
DK172629B1 (da) | 1986-02-14 | 1999-03-22 | Nihon Mediphysics Co Ltd | Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk |
AU8152887A (en) | 1986-10-17 | 1988-05-06 | Cytogen Corporation | Method for preparation of protein-chelator-metal ion compositions suitable for injection |
US4863851A (en) * | 1986-10-20 | 1989-09-05 | The Upjohn Company | Monoclonal antibody to prostate secretory protein |
US5057302A (en) | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
DE3863195D1 (de) | 1987-02-16 | 1991-07-18 | Sumitomo Chemical Co | Feste base, verfahren zu deren herstellung und ihre anwendung fuer die herstellung von olefinen mit innerer doppelbindung. |
US5013645A (en) * | 1987-04-14 | 1991-05-07 | Abbott Laboratories | Immunological methods and materials for detection of tumor associated antigens |
US5531978A (en) | 1987-07-16 | 1996-07-02 | Nycomed Imaging As | Aminopolycarboxylic acids and derivatives thereof |
GB9007965D0 (en) | 1990-04-09 | 1990-06-06 | Nycomed As | Compounds |
ES2086445T3 (es) | 1987-07-16 | 1996-07-01 | Nycomed Imaging As | Acidos aminocarboxilicos y sus derivados. |
US5217704A (en) | 1987-11-06 | 1993-06-08 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
AU619218B2 (en) | 1987-11-06 | 1992-01-23 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
US5130118A (en) | 1987-11-06 | 1992-07-14 | Abbott Laboratories | Methods and materials for the preparation of metal labelled antibody solutions |
US5342924A (en) * | 1987-12-31 | 1994-08-30 | Tanox Biosystems, Inc. | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor |
GB8801646D0 (en) | 1988-01-26 | 1988-02-24 | Nycomed As | Chemical compounds |
US5229289A (en) * | 1988-03-11 | 1993-07-20 | The Biomembrane Institute | Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5118611A (en) * | 1988-07-25 | 1992-06-02 | Adeza Biomedical Corporation | Adenocarcinoma antigen binding methods and reagents |
WO1990009379A1 (en) | 1989-02-10 | 1990-08-23 | Celltech Limited | Aza-macrocycles and processes for their preparation |
US5053503A (en) | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
DE3911816A1 (de) | 1989-04-11 | 1990-10-25 | Hoechst Ag | Substituierte 1,4,7,10-tetraazacyclotridecane, verfahren zu deren herstellung sowie verwendung derselben zur markierung von substanzen mit radionukliden |
US5244816A (en) | 1989-10-11 | 1993-09-14 | Akzo N.V. | Method for purifying chelator conjugated compounds |
EP0453554A4 (en) | 1989-11-13 | 1993-02-17 | Xoma Corporation | Chimeric mouse human antibodies with specificity to hiv antigens |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9115192D0 (en) | 1991-07-12 | 1991-08-28 | Antisoma Ltd | Cancer treatment |
US5227471A (en) * | 1992-01-30 | 1993-07-13 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma |
US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
PT668777E (pt) | 1992-11-05 | 2007-01-31 | Sloan Kettering Inst Cancer | Antigenio de membrana especifico para a prostata |
US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
IL109666A0 (en) | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
US5935818A (en) | 1995-02-24 | 1999-08-10 | Sloan-Kettering Institute For Cancer Research | Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof |
US5599677A (en) * | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
AU2194695A (en) | 1994-03-28 | 1995-10-17 | Regents Of The University Of California, The | Method for preparing radionuclide-labeled chelating agent-ligand complexes |
US6693190B1 (en) | 1994-05-11 | 2004-02-17 | Bracco International B.V. | Enhanced relaxivity monomeric and multimeric compounds |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
ATE458499T1 (de) | 1995-06-07 | 2010-03-15 | Immunomedics Inc | Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort |
IT1283218B1 (it) | 1996-03-08 | 1998-04-16 | Bracco Spa | Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi |
AU725583B2 (en) | 1996-03-25 | 2000-10-12 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6962981B1 (en) * | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5958474A (en) | 1996-08-21 | 1999-09-28 | Nestec S.A. | Process for preparing food flavor precursors |
IT1291623B1 (it) | 1997-04-18 | 1999-01-11 | Bracco Spa | Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici |
WO1999043710A1 (en) | 1998-02-26 | 1999-09-02 | Beckman Coulter, Inc. | Prostate-specific membrane antigens and methods of making and using |
WO2000050457A1 (en) | 1999-02-22 | 2000-08-31 | Beckman Coulter, Inc. | Prostate-specific membrane antigens and methods of making and using |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
WO2000074729A2 (en) | 1999-06-07 | 2000-12-14 | Center For Molecular Medicine And Immunology | Alpha or beta emitters to fragments in radioimmunotherapy |
CA2422291C (en) | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
US7045605B2 (en) | 2001-06-01 | 2006-05-16 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
-
1997
- 1997-04-09 US US08/838,682 patent/US6107090A/en not_active Expired - Lifetime
- 1997-07-17 EA EA200400179A patent/EA200400179A1/ru unknown
- 1997-07-17 PT PT97934922T patent/PT956506E/pt unknown
- 1997-07-17 EP EP97934922A patent/EP0956506B1/de not_active Expired - Lifetime
- 1997-07-17 NZ NZ524036A patent/NZ524036A/xx not_active IP Right Cessation
- 1997-07-17 NZ NZ333683A patent/NZ333683A/en not_active IP Right Cessation
- 1997-07-17 IL IL12797997A patent/IL127979A0/xx not_active IP Right Cessation
- 1997-07-17 ES ES97934922T patent/ES2255723T3/es not_active Expired - Lifetime
- 1997-07-17 CA CA002261018A patent/CA2261018C/en not_active Expired - Lifetime
- 1997-07-17 WO PCT/US1997/012035 patent/WO1998003873A1/en active IP Right Grant
- 1997-07-17 EA EA199900033A patent/EA004634B1/ru not_active IP Right Cessation
- 1997-07-17 JP JP50699598A patent/JP4503102B2/ja not_active Expired - Lifetime
- 1997-07-17 BR BR9710487A patent/BR9710487A/pt not_active Application Discontinuation
- 1997-07-17 EP EP05021545A patent/EP1655605A3/de not_active Withdrawn
- 1997-07-17 AT AT97934922T patent/ATE319089T1/de active
- 1997-07-17 CN CNB2004100544223A patent/CN100344970C/zh not_active Expired - Lifetime
- 1997-07-17 AU AU37976/97A patent/AU733544C/en not_active Expired
- 1997-07-17 CN CNB97197912XA patent/CN1165764C/zh not_active Expired - Lifetime
- 1997-07-17 DE DE69735368T patent/DE69735368T2/de not_active Expired - Lifetime
-
1999
- 1999-07-20 US US09/357,704 patent/US7666425B1/en not_active Expired - Fee Related
- 1999-07-20 US US09/357,709 patent/US7112412B1/en not_active Expired - Fee Related
-
2000
- 2000-08-08 HK HK00104938A patent/HK1025631A1/xx not_active IP Right Cessation
-
2001
- 2001-08-13 US US09/929,665 patent/US20030003101A1/en not_active Abandoned
-
2004
- 2004-05-30 IL IL162230A patent/IL162230A/en not_active IP Right Cessation
-
2009
- 2009-04-06 JP JP2009092429A patent/JP5627191B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE319089T1 (de) | Behandlung und diagnose von krebs | |
DK0914155T3 (da) | Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen | |
DK1064303T3 (da) | Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne | |
JP5468587B2 (ja) | Cd44の表面発現を証明する細胞の細胞毒性媒介 | |
Martinez et al. | Interaction of fibrin with VE‐cadherin | |
Landry et al. | Systemic lupus erythematosus. Studies of the antibodies bound to skin | |
Pereira et al. | Antibodies armed with photosensitizers: from chemical synthesis to photobiological applications | |
Johansson et al. | Comparison of fibronectin receptors from rat hepatocytes and fibroblasts. | |
DE69839123D1 (de) | Prostattumor polynukleotid- und antigenzusammensetzungen | |
TR200003317T2 (tr) | Sintigrafiye özgü bağlama molekülleri, bunları içeren bağlar | |
BR9815289A (pt) | Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado | |
CN105566499B (zh) | 一种多聚体酶‑抗体及其制备方法 | |
Heike et al. | Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. | |
Sofen et al. | Anti-squamous tumor antibodies in patients with squamous cell carcinoma | |
Cordon-Cardo | Immunohistochemical analysis of P-glycoprotein expression in normal and tumor tissues in humans | |
TR200100651T2 (tr) | İki işlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı | |
Cardiff et al. | Extracellular Keratins: An Update | |
Robertson | Characterization and distribution of the human renal cell carcinoma glycoprotein recognized by monoclonal antibody 469-5A | |
MXPA98009346A (en) | A citofluorometric method for determination in serum of antibodies against antigens tumora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0956506 Country of ref document: EP |